Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy
All objectives evaluating DehydraTECH™ drug delivery platform successfully achieved
Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1Dosing is complete in first of three human clinical studies hoped to validate Lexaria’s patented technology for hypertension relief – Study tested an advanced “DehydraTECH™ 2.0” CBD formulation – Second human clinical study, HYPER-H21-2, to commence immediatelyLexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to report that treatment and dosing in its human clinical study (HYPER-H21-1) have been completed ahead of schedule. |